Hyaluronic acid functionalized β-lactoglobulin nanocarriers enhanced tumor targeting and pH-responsive drug release through CD44-mediated endocytosis: in vitro and in vivo assessment
This study demonstrates that hyaluronic acid-functionalized β-lactoglobulin nanocarriers effectively enhance tumor targeting and pH-responsive doxorubicin delivery via CD44-mediated endocytosis, resulting in superior cytotoxicity and tumor growth inhibition with excellent biocompatibility in both in vitro and in vivo models.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Imagine you are trying to deliver a very powerful, but also very dangerous, package to a specific house in a crowded city. If you just throw the package from a truck, it might land in the wrong yard, hurt innocent people, or get lost in the traffic. This is the daily struggle of cancer doctors trying to use chemotherapy drugs. These drugs are like super-strong explosives that can kill cancer cells, but they are so toxic that they also wreck healthy cells along the way, causing terrible side effects. Scientists have been trying to build "smart delivery trucks" called nanocarriers. Think of these as tiny, invisible vehicles that can hide the dangerous drug inside a protective shell, drive it safely through the bloodstream, and only open the door when they arrive at the exact address of the tumor. The big question is: how do we make sure the truck knows exactly where to go and doesn't crash into the wrong buildings?
This is where a team of researchers from Iran and Australia stepped in with a clever new design. They wanted to build a delivery system that could recognize cancer cells by their "uniforms." Cancer cells often wear a specific badge on their surface called a CD44 receptor, which healthy cells usually don't have as much of. The scientists decided to use a protein found in milk, called β-lactoglobulin, as the main body of their truck because it's safe and biodegradable. To make the truck smart, they wrapped it in a special coat made of hyaluronic acid, a natural sugar that acts like a key. This key is designed to fit perfectly into the CD44 lock on cancer cells. They also added a sticky layer in between to help the coat stick tight. The goal was to create a vehicle that stays closed while traveling through the body but opens up quickly once it finds the tumor, releasing the drug exactly where it's needed.
The researchers built these tiny spherical vehicles, which they named BLGNP-DOX/PLL/HA. When they measured them, they found the trucks were about 205 nanometers wide—so small that thousands could fit on the head of a pin. They loaded these trucks with doxorubicin, a common chemotherapy drug. To test if their "smart key" worked, they ran a series of experiments. First, they checked if the trucks could survive the journey through the blood. They found that the vehicles were very friendly to blood cells, causing almost no damage or clotting, which is a great sign for safety.
Then, they tested the trucks in a lab dish with breast cancer cells (MCF-7). The results were exciting: the cancer cells ate up the smart trucks much faster than they ate plain drug or trucks without the special coat. This happened because the hyaluronic acid coat acted like a magnet, grabbing onto the CD44 receptors on the cancer cells and pulling the drug inside. Once inside, the trucks started to break down and release the drug. The scientists noticed something cool: the trucks were "pH-responsive." This means they stayed tightly closed in the normal, neutral environment of the body (pH 7.4), but when they reached the slightly acidic environment of a tumor or inside a cell, they opened up and dumped their cargo. They also found that the trucks released even more drug when they encountered an enzyme called hyaluronidase, which is often found in tumors, acting like a second trigger to ensure the drug gets out.
Finally, the team took their show on the road by testing these trucks in mice with breast tumors. They gave the mice the smart trucks, plain trucks, or just the drug by itself. The mice treated with the smart trucks showed the best results: their tumors grew much slower than in the other groups. Importantly, the mice didn't get as sick as those treated with the plain drug; their blood counts and liver health remained much closer to normal. The study suggests that this milk-protein-based, sugar-coated delivery system is a promising way to target cancer more precisely and safely, though the researchers note this is still a preclinical proof of concept, meaning it has shown great promise in the lab and in mice, but needs more testing before it can help people.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.